UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934

November 5, 2020

Date of report (Date of earliest event reported)

Axsome Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) **001-37635** (Commission File Number) **45-4241907** (IRS Employer Identification No.)

22 Cortlandt Street, 16th Floor New York, New York

(Address of principal executive offices)

10007 (Zip Code)

Registrant's telephone number, including area code (212) 332-3241

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock, Par Value \$0.0001 Per Share	AXSM	The Nasdaq Global Market

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 🖂

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2020, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2020 and provided an update on the Company's operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

A copy of the presentation that the Company used in connection with its conference call to discuss its financial results and business update is filed as Exhibit 99.2 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description	
99.1	Press Release dated November 5, 2020.	
99.2	<u>Third Quarter 2020 Financial Results Presentation.</u>	
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Axsome Therapeutics, Inc.

By:/s/ Herriot Tabuteau, M.D.Name:Herriot Tabuteau, M.D.Title:President and Chief Executive Officer

Dated: November 5, 2020



Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed

NDA submissions for AXS-05 in depression expected in January 2021, and for AXS-07 in migraine expected in 1Q 2021

Launch readiness activities progressing with buildout of Digital-Centric Commercialization (DCCTM) platform

Efficacy results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD, and suicidal ideation, on track for 4Q 2020

Efficacy results from MOVEMENT Phase 3 open-label trial of AXS-07 in migraine expected in 4Q 2020

Phase 3 trial of AXS-05 in Alzheimer's disease agitation on track for initiation in 4Q 2020

Phase 3 trial of AXS-12 in narcolepsy on track for initiation in 1Q 2021

FDA meeting for AXS-14 in fibromyalgia scheduled for 1Q 2021

Company to host conference call today at 8:00 AM Eastern

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2020.

"Over the past several months, we continued to advance our AXS-05 and AXS-07 product candidates towards NDA submissions in major depressive disorder and migraine, and intensified our commercial launch readiness activities," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "We also advanced the rest of our late-stage pipeline holding two positive FDA Breakthrough Therapy designation meetings, one for AXS-05 in Alzheimer's disease agitation, and one for AXS-12 in narcolepsy, resulting in expedited development paths for both programs. Non-dilutive committed capital from our new term loan facility combined with our cash provide financial resources approaching \$400 million, positioning us well for our two potential product launches starting next year. Our intellectual property portfolio continues to grow with recently issued and allowed patents for AXS-05 in depression which now provide protection out to 2040. We anticipate an active next few months as we complete our NDA submissions for AXS-05 and AXS-07, release topline efficacy data from open-label trials with these product candidates, initiate Phase 3 trials for AXS-05 in Alzheimer's disease agitation and for AXS-12 in narcolepsy, and meet with FDA on AXS-14 for the treatment of fibromyalgia."

CNS Pipeline Update

For the many people living with serious CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. The Company is developing a portfolio of differentiated, patent-protected, central nervous system (CNS) product candidates with four in active clinical development.

AXS-05: AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is Axsome's novel, oral, investigational NMDA receptor
antagonist with multimodal activity being developed for the following indications: major depressive disorder (MDD), Alzheimer's disease
(AD) agitation, and smoking cessation. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy
designations for MDD, and for AD agitation; as well as Fast Track designations for treatment resistant MDD (TRD), and for AD agitation.

Depression: Pre-submission activities for Axsome's New Drug Application (NDA) to the FDA for AXS-05 for the treatment of MDD are nearing completion. Due to a COVID-related logistical delay from one vendor, the Company now expects to submit the NDA in January instead of by year-end.

Axsome has completed the COMET (Clinical Outcomes with NMDA-based Depression Treatment) Phase 3 open-label, long-term safety trial to support the planned NDA filing of AXS-05 in MDD. The three Phase 2 open-label efficacy sub-studies of the COMET trial have also been completed. These sub-studies are evaluating the efficacy and safety of AXS-05 in three clinically pertinent MDD patient populations: the COMET-TRD trial in treatment resistant MDD (TRD), the COMET-AU trial in antidepressant unresponsive MDD, and the COMET-SI trial in MDD with suicidal ideation. Efficacy results from these studies are on track to be reported in the fourth quarter of 2020.

Axsome is conducting the MERIT (Mechanistic Evaluation of Response in TRD) trial, a Phase 2, double-blind, placebo-controlled, randomized withdrawal study in patients with TRD. Results from the MERIT trial are on track to be reported in the first half of 2021.

AD Agitation: In June 2020, Axsome received FDA Breakthrough Therapy designation for AXS-05 for the treatment of AD agitation. The designation was supported by the positive results from the pivotal ADVANCE-1 study.

In August 2020, Axsome announced the results of an FDA Breakthrough Therapy meeting for AXS-05 for the treatment of AD agitation. Results of the meeting confirmed the pivotal status of the ADVANCE-1 trial, and the establishment of the superiority of AXS-05 over its components (component contribution) in the treatment of AD agitation. Consequently, only one additional Phase 3 efficacy trial is needed to support the filing of an NDA and only a placebo control will be required for this trial. This additional Phase 3 efficacy trial will be conducted using a randomized-withdrawal design, in which all patients are first treated with open-label AXS-05, with the patients experiencing a treatment response being subsequently randomized in a double-blind fashion to continued treatment with AXS-05 or to switch to placebo. Axsome is on track to initiate this Phase 3 trial this quarter.

Smoking Cessation: Axsome is scheduled to meet with the FDA in the first quarter of 2021 to discuss the continued clinical development of AXS-05 as an aid to smoking cessation treatment. Axsome previously announced positive results from a Phase 2 trial of AXS-05 for smoking cessation treatment conducted under a research collaboration between Axsome and Duke University.

• AXS-07: AXS-07 (MoSEIC[™] meloxicam/rizatriptan) is Axsome's novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine.

Migraine: Pre-submission activities for the Company's NDA for AXS-07 in the acute treatment of migraine are progressing with major NDA-related items on track for completion by year-end. Axsome now plans to submit the NDA to the FDA in the first quarter of 2021, versus previous guidance of the fourth quarter of 2020, to allow for inclusion of supplemental manufacturing information to ensure a robust submission package.

Axsome has completed the MOVEMENT (Multimechanistic Treatment Over Time of Migraine Symptoms) Phase 3 open-label, long-term safety trial to support the planned NDA filing of AXS-07 in the acute treatment of migraine. Axsome expects to announce efficacy results from this trial this quarter.

 AXS-12: AXS-12 (reboxetine) is Axsome's novel, oral, potent, and highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. AXS-12 has been granted FDA Breakthrough Therapy designation for the treatment of cataplexy in patients with narcolepsy and Orphan Drug Designation for the treatment of narcolepsy.

Narcolepsy: In August 2020, Axsome received FDA Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in patients with narcolepsy. The designation was supported by the positive results from the Phase 2 CONCERT study.

In September 2020, Axsome announced the expedited development status and plan for AXS-12 for the treatment of narcolepsy following an FDA Breakthrough Therapy meeting. The expedited development plan includes one Phase 3 efficacy trial, which, along with the previously completed Phase 2 CONCERT trial, will be used to support the filing of an NDA for approval of AXS-12 for the treatment of cataplexy in narcolepsy. The planned Phase 3 trial will be a randomized, double-blind, placebo-controlled, parallel-group study. Axsome is on track to initiate this Phase 3 trial in the first quarter of 2021.

• AXS-14: AXS-14 (esreboxetine) is Axsome's novel, oral, potent, and highly selective norepinephrine reuptake inhibitor for the treatment of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.

Fibromyalgia: Axsome is scheduled to meet with the FDA in the first quarter of 2021 to discuss the further clinical development of AXS-14 for the treatment of fibromyalgia. AXS-14 has previously met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and a Phase 2 trial in the treatment of fibromyalgia.

Anticipated Milestones

- NDA Filings:
 - 0 AXS-05 in the treatment of MDD (January 2021)
 - 0 AXS-07 in the acute treatment of migraine (1Q 2021)

• Clinical Trial Readouts:

- 0 Phase 2 COMET-TRD trial of AXS-05 in TRD, topline data (4Q 2020)
- 0 Phase 2 COMET-AU trial of AXS-05 in antidepressant unresponsive MDD, topline data (4Q 2020)
- 0 Phase 2 COMET-SI trial of AXS-05 in MDD with suicidal ideation, topline data (4Q 2020)
- 0 Phase 2 MERIT trial of AXS-05 in TRD, topline data (1H 2021)

• Clinical Trial Initiations:

- 0 Phase 3 trial of AXS-05 in AD agitation (4Q 2020)
- 0 Phase 3 trial of AXS-12 in narcolepsy (1Q 2021)
- FDA Meetings:
 - 0 AXS-05 for smoking cessation (1Q 2021)
 - 0 AXS-14 for fibromyalgia (1Q 2021)

Commercial Update

• In November 2020, Axsome and Veeva Systems announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC[™]) platform. The partnership with Veeva is part of the continuing build of Axsome's DCC platform in preparation for the potential launches of AXS-05 for depression and AXS-07 for migraine. The Axsome DCC platform is a proprietary approach to commercialization that incorporates specialized digital tools, proprietary data and analytics, integrated systems, and an intelligent operating model. Through this digital platform, Axsome aims to optimize physician and patient engagements, enhance engagement quality, and increase the effectiveness of promotional efforts as compared to traditional approaches.

Corporate Update

• In September 2020, Axsome secured a \$225 million term loan facility with Hercules Capital. Under the terms of this facility, \$60 million can be drawn at closing; \$115 million may be drawn at the Company's option, in three separate tranches, upon approval of AXS-05 in MDD, upon approval of AXS-07 in migraine, and upon certain combined sales criteria for AXS-05 and AXS-07; and an additional \$50 million is available, subject to the approval of Hercules Capital, to support future strategic initiatives, including further pipeline advancement or expansion. The committed capital strengthens the Company's balance sheet through the anticipated commercial launches of AXS-05 for MDD and AXS-07 for migraine, and extends its cash runway into at least 2024, based on current operating plans.

Third Quarter 2020 Financial Results

- Research and development (R&D) expenses: R&D expenses were \$14.8 million for the quarter ended September 30, 2020 and \$15.8 million for the comparable period in 2019. The decrease of \$1.0 million was driven by the completion of several clinical trials which were ongoing in the comparable prior period.
- General and administrative (G&A) expenses: G&A expenses were \$6.3 million for the quarter ended September 30, 2020 and \$3.1 million for the comparable period in 2019. The change was primarily due to an increase in stock compensation expense, along with the build-out of the commercial function.
- Net loss: Net loss was \$22.9 million, or \$(0.61) per share, which includes a \$1.3 million one-time charge related to the extinguishment of the previous debt facility, for the quarter ended September 30, 2020, compared to a net loss of \$19.1 million, or \$(0.56) per share for the comparable period in 2019.
- Cash: At September 30, 2020, Axsome had \$202.4 million of cash compared to \$190.7 million of cash at June 30, 2020.
- Shares outstanding: At September 30, 2020, Axsome had 37,344,201 shares of common stock outstanding.
- **Financial Guidance:** Axsome believes that its cash at September 30, 2020 along with the committed capital from Hercules facility will be sufficient to fund the Company's anticipated operations, based on its current operating plans, into at least 2024.

Conference Call Information

Axsome will host a conference call and webcast with slides today at 8:00 AM Eastern to discuss third quarter 2020 financial results as well as to provide a corporate update. To participate in the live conference call, please dial (866) 393-4306 (toll-free domestic) or (734) 385-2616 (international), and use the conference ID 4382529. The live webcast can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five product candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA. For more information, please visit the Company's website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.

Forward Looking Statements

Certain matters discussed in this press release are "forward-looking statements". We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application ("NDA") for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration ("FDA") or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, FDA's agreement with the Company's discontinuation of the bupropion treatment arm of the ADVANCE-1 study in accordance with the independent data monitoring committee's recommendations); the potential for the MOMENTUM clinical trial to provide a basis for approval of AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment; the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's product candidates, if approved; the Company's anticipated capital requirements, including the Company's anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forwardlooking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forwardlooking statements to reflect subsequent events or circumstance.



Axsome Therapeutics, Inc. Selected Consolidated Financial Data

Statements of Operations Information:

	Three months ended September 30,		
	 2020		2019
Operating expenses:			
Research and development	\$ 14,795,493	\$	15,835,573
General and administrative	6,331,308		3,111,662
Total operating expenses	 21,126,801		18,947,235
Loss from operations	(21,126,801)		(18,947,235)
Interest income (expense)	(551,002)		(327,825)
Tax Credit			139,448
Loss on extinguishment of debt	(1,247,012)		—
Net loss	\$ (22,924,815)	\$	(19,135,612)
Net loss per common share, basic and diluted	\$ (0.61)	\$	(0.56)
Weighted average common shares outstanding, basic and diluted	37,311,726		34,445,489

Balance Sheet Information:

	Sept	tember 30, 2020	December 31, 2019
Cash and cash equivalents	\$	202,360,292	\$ 219,966,167
Total assets		203,629,404	220,549,760
Loan payable, current and long-term		48,026,108	19,934,918
Accumulated deficit		(249,631,446)	(175,895,493)
Stockholders' equity	\$	135,261,758	\$ 178,722,389

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com



3Q 2020 Financial Results and Business Update November 5, 2020

© Axsome Therapeutics, Inc.

Forward-Looking Statements & Safe Harbor

Certain information contained in this presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials and the number or type of studies or nature of results necessary to support the filing of a new drug application for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration ("FDA") or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, FDA's agreement with the Company's discontinuation of the bupropion treatment arm of the ADVANCE-1 study in accordance with the independent data monitoring committee's recommendations); the Company's ability to obtain additional capital necessary to fund its operations; the Company's ability to generate revenues in the future; the potential for the MOMENTUM clinical trial to provide a basis for approval of AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment; the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the enforceability of the Company's license agreements; the acceptance by the market of the Company's product candidates, if approved; the Company's anticipated capital requirements, including the Company's anticipated cash runway; and other factors, including general economic conditions and regulatory developments, not within the Company's control. These factors could cause actual results and developments to be materially different from those expressed in or implied by such statements. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, these projections, assumptions and estimates are necessarily subject to a high degree of uncertainty and risk.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Axsome Therapeutics 1Q 2020 Financial Results and Business Update

Introduction	Mark Jacobson, Chief Operating Officer	
Business Update	Herriot Tabuteau, MD, Chief Executive Officer	
Commercialization Update	Lori Englebert, Sr VP, Commercial & Business Development	
Financial Results	Nick Pizzie, Chief Financial Officer	
Q&A	Presenters Cedric O'Gorman, MD, Sr VP Clinical Development & Medical Affairs	
Concluding Remarks	Herriot Tabuteau, MD, Chief Executive Officer	

AXSOME THERAPEUTICS


© Axsome Therapeutics, Inc.

Axsome Therapeutics 3Q 2020

- COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed
- NDA submissions for AXS-05 in depression expected in January 2021, and for AXS-07 in migraine expected in 1Q 2021
- Launch readiness activities progressing with buildout of Digital-Centric Commercialization (DCC[™]) platform
- Efficacy results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD, and suicidal ideation, on track for 4Q 2020
- Efficacy results from MOVEMENT Phase 3 open-label trial of AXS-07 in migraine expected in 4Q 2020
- Phase 3 trial of AXS-05 in Alzheimer's disease agitation on track for initiation in 4Q 2020
- Phase 3 trial of AXS-12 in narcolepsy on track for initiation in 1Q 2021
- FDA meeting for AXS-14 in fibromyalgia scheduled for 1Q 2021


AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.



Prevalence of Depression Symptoms Before and During Pandemic

• Depression increased more than 3 fold due to pandemic and skewed toward those with more severe symptoms



1) Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open. 2020;3(9):e2019686. doi:10.1001/jamanetworkopen.2020.19686

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

High Unmet Needs Exist for MDD Patients

Unmet Need ¹	Reason for Unmet Need
New, patient-friendly treatment options	There have been no new oral MOA to treat MDD since 1959 (61 years) ²
Faster onset of action	Current therapies typically take 6-8 weeks to reach meaningful response ³
Achievement of remission	Only ~1/4 of patients on standard antidepressants achieve remission within 10-14 weeks ⁴
Efficacy without safety/tolerability trade-offs	Current therapies are typically associated with weight gain, sexual disfunction ⁵ , and cognitive impairments

1) Internal primary market research; 2) Thomas, D., & Wessel, C. (2017). The State of Innovation in Highly Prevalent Chronic Diseases: Volume 1: Depression Therapies, BIO 3) Rush AJ, et al. Am J Psychiatry 2006;163:1905-1917; 4) Machado-vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA. J Clin Psychiatry. 2008;69(6):946-958. 5) Ferguson JM. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-27

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

AXS-05 would be the first new oral MOA to treat MDD in over 60 years

Class	Tricyclics and MAOIs	Tetracyclics, Dopamine targeting	SSRI/SNRIs	Monoamine targeting	NMDA+	NMDA+
Products Approved / Route	8 approved Oral	6 approved Oral	10 approved Oral	5 approved Oral	Esketamine Intranasal	AXS-05 Oral
моа		Monoaminerg	ic Modulation		Glutama Modul	
Years of Introduction	1959 - 1969	1970 - 1986	1987-2006	2007-2016	2019	2021 E

Source: Thomas, D., & Wessel, C. (2017). The State of Innovation in Highly Prevalent Chronic Diseases: Volume 1: Depression Therapies, BIO.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Depression

Summary of AXS-05 Clinical Profile in Completed MDD Trials


MOA	 First new orally administered MOA to treat MDD in over 60 years Oral NMDA receptor antagonist targeting the glutamatergic pathway Monotherapy
Clinician Reported Efficacy	 Rapid and sustained improvement in MADRS total score vs. placebo and vs. bupropion Rapid and sustained achievement of remission and clinical response Statistically significant symptom improvement as early as week 1, sustained at least through week 6
Patient Reported Efficacy	 Rapid and sustained improvement in quality of life Rapid and sustained improvement in QIDS-SR-16 Statistically significant symptom improvement as early as week 1, sustained at least through week 6
Safety / Tolerability	 Favorable safety and tolerability profile in completed clinical trials Not associated with weight gain, increased sexual dysfunction, cognitive impairment, or psychotomimetic effects

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Preparing For AXS-05 Launch: Digital Centric CommercializationTM (DCC) Platform

Using digital to redefine patient care by providing meaningful, optimized customer engagements




AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.


Preparing For AXS-05 Launch: Key Trends – HCPs

DCC™



DCC™

Preparing For AXS-05 Launch: Key Trends – Patients



In 2018, time spent with digital surpassed traditional media for the first time and in 2020 is almost 25% higher

Digital includes mobile (non-voice: radio, social networks, video and other), desktop/laptop (video, social networks, radio and other), and other connected devices. Traditional includes TV, radio, print (newspapers and magazines) and other; does not include digital. Source: Statista.com

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

DCC™

Preparing For AXS-05 Launch: Initial Engagement Launch Strategy





- Extensive use of remote detailing, with traditional as needed
- Focused targeting of psychiatrists and mental health focused PCPs

Patients



Primarily digital engagement

13


- Omnichannel approach
- Focused targeting

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Preparing For AXS-05 Launch: Digital Centric CommercializationTM (DCC) Platform

Using digital to redefine patient care by providing meaningful, optimized customer engagements



Financial Update

Nick Pizzie

AXSOME THERAPEUTICS

15

CHIEF FINANCIAL OFFICER AXSOME THERAPEUTICS, INC.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Key Financial Information

(in millions) Cash and Cash Equivalents	\$ <u>3Q '20</u> 202.4	\$ <u>2Q '20</u> 190.7
	3Q '20	<u>3Q '19</u>
Research & Development	\$ 14.8	\$ 15.8
General & Administrative	\$ 6.3	\$ 3.1
Interest Expense	\$ 0.6	\$ 0.3
Tax Credit	\$ -	\$ (0.1)
Debt Extinguishment	\$ 1.2	\$ -
Net Loss	\$ 22.9	\$ 19.1

• **Financial guidance**: Cash, along with committed capital from term loan facility, anticipated to fund operating requirements into at least 2024.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Q&A

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Concluding Remarks

Herriot Tabuteau, MD

CHIEF EXECUTIVE OFFICER AXSOME THERAPEUTICS, INC.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Our CNS Candidates and Pipeline

- Four differentiated clinical-stage CNS assets targeting significant and growing markets
- Patent protection to 2034-2040, worldwide rights for most product candidates

Product Candidate / MOA	Phase 1	Phase 2	Phase 3	NDA	
	Major Depressive Disorder: B	reakthrough Therapy Designati	on		
AXS-05 NMDA receptor antagonist	Alzheimer's Disease Agitation: Breakthrough Therapy Designation				
with multimodal activity	Smoking Cessation				
AXS-07					
MoSEIC™ COX-2 pref. inhibitor + 5-HT _{18/1D} agonist	Migraine				
AXS-12 Highly selective NE reuptake inhibitor	Narcolepsy: Orphan & Breakt	hrough Therapy Designations			
AXS-14					
Highly selective NE reuptake inhibitor	Fibromyalgia				

Abbreviations: CNS = Central Nervous System; NE = Norepinephrine.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

Our Clinical and Regulatory Milestones

Product Candidate	Indication	Milestone
AXS-05 NMDA receptor antagonist with multimodal activity	MDD	 STRIDE-1 topline results Pre-NDA meeting COMET completion COMET-AU / SI / TRD sub-study results (4Q 2020) MERIT results (1H 2021) NDA submission (Jan. 2021)
	AD Agitation	 ADVANCE-1 topline results FDA Breakthrough Therapy designation Phase 3 trial start (4Q 2020)
	Smoking Cessation	• FDA meeting (1Q 2021)
AXS-07 MoSEIC™ COX-2 pref. inhibitor + 5-HT _{1B/1D} agonist	Migraine	 ✓ INTERCEPT topline results ✓ Pre-NDA meeting ✓ MOVEMENT completion MOVEMENT results (4Q 2020) NDA submission (1Q 2021)
AXS-12 Highly selective NE reuptake inhibitor	Narcolepsy	 FDA Breakthrough Therapy designation Phase 3 trial start (1Q 2021)
AXS-14 Highly selective NE reuptake inhibitor	Fibromyalgia	• FDA meeting (1Q 2021)

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

AXSOME THERAPEUTICS

Thank you.

For more information, please contact Mark Jacobson Chief Operating Officer 212-332-3243 mjacobson@Axsome.com

axsome.com